By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Astex Pharmaceuticals 

4140 Dublin Boulevard
Suite 220
Dublin  California  94568  U.S.A.
Phone: 925-560-0100 Fax: 925-560-0101


SEARCH JOBS
Astex Pharmaceuticals is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.


•Fiscal strength with significant cash, ongoing revenues and potential milestone payments


•Productive partnerships with top-tier pharmaceutical companies


•Rich product portfolio with multiple drugs in clinical development


•Visionary leadership backed by a world-class management team


Oncology Focused. We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.


Financially Strong. We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.



Key Statistics


Email: info@astx.com
Ownership: Public

Web Site: Astex Pharmaceuticals
Employees: 95
Symbol: ASTX
 



Industry
Pharmaceutical

Segment
Drug Discovery





Company News
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014 8:49:34 AM
Astex Pharmaceuticals (ASTX) to Present at American Association for Cancer Research-National Cancer Institute-EORTC 10/15/2013 9:30:29 AM
Otsuka Pharmaceutical Co., Ltd. Completes Acquisition of Astex Pharmaceuticals (ASTX) 10/11/2013 9:53:16 AM
Astex Pharmaceuticals (ASTX) Responds to Further Misleading Claims Made by Sarissa Capital 10/10/2013 9:33:47 AM
Astex Pharmaceuticals (ASTX) Announces Expiration of HSR Waiting Period for Pending Transaction 10/7/2013 9:39:36 AM
Astex Pharmaceuticals (ASTX) Shareholder Opposes $886 Million Bid by Otsuka Pharmaceutical Co., Ltd. 10/3/2013 7:01:05 AM
Astex Pharmaceuticals (ASTX) Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress 9/30/2013 9:02:45 AM
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals (ASTX) 9/5/2013 7:25:09 AM
Astex Pharmaceuticals (ASTX) to Present at Investor Conferences in September 9/3/2013 9:46:14 AM
Astex Pharmaceuticals (ASTX) Sees Positive Results From SGI-110 AML Phase 2 Study; Stock Rockets +24.45% at Market Close (August 28, 2013) 8/28/2013 6:55:45 AM
12345678910...
//-->